Invitation - Presentation of Sobi's Q4/FY 2018 Results

News provided by

Feb 11, 2019, 08:48 ET

STOCKHOLM, Feb. 11, 2019 /PRNewswire/ -- On 20 February, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the fourth quarter and full year 2018. Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 14:00 CET. The event will be hosted by Sobi's CEO and President, Guido Oelkers, and the presentation will be held in English.

The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi's website prior to the telephone conference.

To participate in the telephone conference, please call:

SE: +46-8-505-583-53

UK: +44-33-330-092-73

US: +1-646-722-49-02

Click here to go to the live webcast.

After the live event the webcast will be available on-demand via the same URL.

About Sobi™

Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our vision is to be recognised as a global leader in providing access to innovative treatments that transform lives for individuals with rare diseases. The product portfolio is primarily focused on treatments in Haemophilia, Immunology and Specialty Care. Partnering in the development and commercialisation of products in specialty care is a key element of our strategy. Sobi has pioneered in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2017, Sobi had total revenues of SEK 6.5 billion and approximately 850 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.

For more information please contact

Media relations/Investor relations	Investor relations
Linda Holmström, Senior Communications/IR Manager	Jörgen Winroth, Senior IR Advisor
+46 708 734 095	+1 347 224 0819, +1 212 579 0506
[email protected]	[email protected]
Paula Treutiger, Head of Communications & Investor Relations
+46 733 666 599
[email protected]